Differential alterations of neocortical GluN receptor subunits in patients with mixed subcortical ischemic vascular dementia and Alzheimer's disease

Journal of Alzheimer's Disease

Volumn 44, Issue 2, 2015, Pages 431-437

  Mohamed, Nur Ezan ^a   Lee, Jasinda H ^a   Francis, Paul T ^b   Esiri, Margaret M ^c   Chen, Christopher P ^a,d   Lai, Mitchell K P ^a,b,d  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d NATIONAL UNIVERSITY HEALTH SYSTEM   (Singapore)

Author keywords

Alzheimer's disease; GluN receptors; mixed dementia; neurochemistry; subcortical ischemic vascular dementia

Indexed keywords

N METHYL DEXTRO ASPARTIC ACID RECEPTOR 1; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 2A; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 2B; RECEPTOR ANTIBODY; GRIN1 PROTEIN, HUMAN; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N-METHYL D-ASPARTATE RECEPTOR SUBTYPE 2A; NERVE PROTEIN; NR2B NMDA RECEPTOR;

AGED; ALZHEIMER DISEASE; ARTICLE; AUTOPSY; BRAIN ISCHEMIA; BRAIN TISSUE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FOLLOW UP; GENE LOSS; HUMAN; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOREACTIVITY; LACUNAR STROKE; MALE; MULTIINFARCT DEMENTIA; NEOCORTEX; PRIORITY JOURNAL; UPREGULATION; COMPARATIVE STUDY; LONGITUDINAL STUDY; METABOLISM; PATHOLOGY; SEVERITY OF ILLNESS INDEX; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; DEMENTIA, VASCULAR; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOBLOTTING; LONGITUDINAL STUDIES; MALE; NEOCORTEX; NERVE TISSUE PROTEINS; RECEPTORS, N-METHYL-D-ASPARTATE; SEVERITY OF ILLNESS INDEX;

EID: 84921505060     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-141764     Document Type: Article

References (35)

1. Jellinger KA (2013) Pathology and pathogenesis of vascular cognitive impairment-A critical update. Front Aging Neurosci 5, 17.
2. Román GC, Erkinjuntti T, Wallin A, Pantoni L, Chui HC (2002) Subcortical ischaemic vascular dementia. Lancet Neurol 1, 426-436.
3. Tierney MC, Black SE, Szalai JP, Snow WG, Fisher RH, Nadon G, Chui HC (2001) Recognition memory and verbal fluency differentiate probable Alzheimer disease from subcortical ischemic vascular dementia. Arch Neurol 58, 1654-1659.
4. Hachinski V, Iadecola C, Petersen RC, Breteler MM, Nyenhuis DL, Black SE, Powers WJ, DeCarli C, Merino JG, Kalaria RN, Vinters HV, Holtzman DM, Rosenberg GA, Wallin A, Dichgans M, Marler JR, Leblanc GG (2006) National Institute of Neurological Disorders and Stroke-Canadian Stroke Network vascular cognitive impairment harmonization standards. Stroke 37, 2220-2241.
5. Jellinger KA, Attems J (2007) Neuropathological evaluation of mixed dementia. J Neurol Sci 257, 80-87.
6. Bailey TL, Rivara CB, Rocher AB, Hof PR (2004) The nature and effects of cortical microvascular pathology in aging and Alzheimer's disease. Neurol Res 26, 573-578.
7. Kalback W, Esh C, Castano EM, Rahman A, Kokjohn T, Luehrs DC, Sue L, Cisneros R, Gerber F, Richardson C, Bohrmann B, Walker DG, Beach TG, Roher AE (2004) Atherosclerosis, vascular amyloidosis and brain hypoperfusion in the pathogenesis of sporadic Alzheimer's disease. Neurol Res 26, 525-539.
8. O'Brien JT, Erkinjuntti T, Reisberg B, Roman G, Sawada T, Pantoni L, Bowler JV, Ballard C, DeCarli C, Gorelick PB, Rockwood K, Burns A, Gauthier S, DeKosky ST (2003) Vascular cognitive impairment. Lancet Neurol 2, 89-98.
9. Iadecola C (2010) The overlap between neurodegenerative and vascular factors in the pathogenesis of dementia. Acta Neuropathol 120, 287-296.
10. Bartus RT, Dean RL, III, Beer B, Lippa AS (1982) The cholinergic hypothesis of geriatric memory dysfunction. Science 217, 408-414.
11. Cacabelos R, Takeda M, Winblad B (1999) The glutamatergic system and neurodegeneration in dementia: Preventive strategies in Alzheimer's disease. Int J Geriatr Psychiatry 14, 3-47.
12. Francis PT (2003) Glutamatergic systems in Alzheimer's disease. Int J Geriatr Psychiatry 18, S15-S21.
13. Hunt DL, Castillo PE (2012) Synaptic plasticity of NMDA receptors: Mechanisms and functional implications. Curr Opin Neurobiol 22, 496-508.
14. Francis PT, Parsons CG, Jones RW (2012) Rationale for combining glutamatergic and cholinergic approaches in the symptomatic treatment of Alzheimer's disease. Expert Rev Neurother 12, 1351-1365.
15. Hynd MR, Scott HL, Dodd PR (2004) Glutamate-mediated excitotoxicity and neurodegeneration in Alzheimer's disease. Neurochem Int 45, 583-595.
16. Dingledine R, Borges K, Bowie D, Traynelis SF (1999) The glutamate receptor ion channels. Pharmacol Rev 51, 7-62.
17. Hynd MR,Scott HL, Dodd PR(2004) Selective loss ofNMDA receptor NR1 subunit isoforms in Alzheimer's disease. J Neurochem 89, 240-247.
18. Mishizen-Eberz AJ, Rissman RA, Carter TL, Ikonomovic MD, Wolfe BB, Armstrong DM (2004) Biochemical and molecular studies of NMDA receptor subunits NR1/2A/2B in hippocampal subregions throughout progression of Alzheimer's disease pathology. Neurobiol Dis 15, 80-92.
19. Sze C, Bi H, Kleinschmidt-DeMasters BK, Filley CM, Martin LJ (2001) N-Methyl-D-aspartate receptor subunit proteins and their phosphorylation status are altered selectively in Alzheimer's disease. J Neurol Sci 182, 151-159.
20. Tsang SW, Pomakian. J, Marshall GA,Vinters HV, Cummings JL, Chen CP,Wong PT, Lai MK (2007) Disrupted muscarinic M1 receptor signaling correlates with loss of protein kinase C activity and glutamatergic deficit in Alzheimer's disease. Neurobiol Aging 28, 1381-1387.
21. Tsang SW,Vinters HV, Cummings JL,Wong PT, Chen CP, Lai MK (2008) Alterations in NMDA receptor subunit densities and ligand binding to glycine recognition sites are associated with chronic anxiety in Alzheimer's disease. Neurobiol Aging 29, 1524-1532.
22. Hynd MR, Scott HL, Dodd PR (2004) Differential expression of N-methyl-D-aspartate receptor NR2 isoforms in Alzheimer's disease. J Neurochem 90, 913-919.
23. Kirvell SL, Elliott MS, Kalaria RN, Hortobagyi T, Ballard CG, Francis PT (2010) Vesicular glutamate transporter and cognition in stroke: A case-control autopsy study. Neurology 75, 1803-1809.
24. Folstein MF, Folstein SE, McHugh PR (1975) "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12, 189-198.
25. Mirra SS, Heyman A,McKeel D, Sumi SM, Crain BJ, Brownlee LM, Vogel FS, Hughes JP, van Belle G, Berg L (1991) The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 41, 479-486.
26. Braak H, Braak E (1991) Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 82, 239-259.
27. Román GC, Tatemichi TK, Erkinjuntti T, Cummings JL, Masdeu JC, Garcia JH, Amaducci L, Orgogozo JM, Brun A, Hofman A (1993) Vascular dementia: Diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology 43, 250-260.
28. Kalaria RN, Kenny RA, Ballard CG, Perry R, Ince P, Polvikoski T (2004) Towards defining the neuropathological substrates of vascular dementia. J Neurol Sci 226, 75-80.
29. Esiri MM,Wilcock GK, Morris JH (1997) Neuropathological assessment of the lesions of significance in vascular dementia. J Neurol Neurosurg Psychiatry 63, 749-753.
30. Lai MK,Lai OF,Keene J, Esiri MM,Francis PT, Hope T, Chen CP(2001) Psychosis of Alzheimer's disease is associated with elevated muscarinic M2 binding in the cortex. Neurology 57, 805-811.
31. Thomas SJ, Grossberg GT (2009) Memantine: A review of studies into its safety and efficacy in treating Alzheimer's disease and other dementias. Clin Interv Aging 4, 367-377.
32. Mohamed NE, Zhao Y, Lee JH, Tan MG, Esiri MM,Wilcock GK, Smith AD,Wong PT, Chen CP, Lai MK(2011) Upregulation ofAMPAreceptor GluR2 (GluA2) subunits in subcortical ischemic vascular dementia is repressed in the presence of Alzheimer's disease. Neurochem Int 58, 820-825.
33. Calabresi P, Pisani A, Mercuri NB, Bernardi G (1992) Longterm potentiation in the striatum is unmasked by removing the voltage-dependent magnesium block of NMDA receptor channels. Eur J Neurosci 4, 929-935.
34. Reed BR, Eberling JL, Mungas D, Weiner M, Kramer JH, Jagust WJ (2004) Effects of white matter lesions and lacunes on cortical function. Arch Neurol 61, 1545-1550.
35. Gold G, Kovari E, Herrmann FR, Canuto A, Hof PR, Michel JP, Bouras C, Giannakopoulos P (2005) Cognitive consequences of thalamic, basal ganglia, and deep white matter lacunes in brain aging and dementia. Stroke 36, 1184-1188.